Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 170Rituximab 164Specimen Handling 116Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 86Doxorubicin 81Prednisone 78fludarabine 70venetoclax 69obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 44Etoposide 43CT-P10 42blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 34Gemcitabine 33zanubrutinib 31prednylidene 31pembrolizumab 30glofitamab 30deltacortene 30Calcium Dobesilate 30Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endoscopy, Gastrointestinal × Lymphoid × 90 days × Clear all
NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡